employed fluorinated polyamidoamine (FP) for miR‐23b delivery, which was nonspecifically taken up by FLSs in vivo and resulted in the restoration of miR‐23b levels in the synovium along with a significant reduction in inflammatory factors (TNF‐α, IL‐1β, and IL‐6).[215] Treatment with FP/miR‐23b suppressed inflammation and increased bone density (FP/miR‐23b group, 5994.66 mg/cc vs untreated group, 5362.3 mg/cc) in AIA mice, ameliorating typical RA symptoms. The gene discussed is IL1B; the disease is rheumatoid arthritis.